Jaguar Animal Health Inc
$ 1.04
7.63%
30 Jul - close price
- Market Cap 5,106,800 USD
- Current Price $ 1.04
- High / Low $ 1.07 / 0.97
- Stock P/E N/A
- Book Value -38.12
- EPS -695.50
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE -4.12 %
- 52 Week High 92.75
- 52 Week Low 0.91
About
Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
Analyst Target Price
$262.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-12 | 2024-08-12 | 2024-04-01 | 2024-01-31 | 2023-11-13 | 2023-08-13 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -219.8 | -259.26 | -16.7 | -4403 | -918.75 | -3535 | -3459.75 | -33 | -19949.98 | -36224.96 | -125474.87 | -3.4297 |
| Estimated EPS | -177.8 | -249.55 | -10.82 | -647.5 | -2073.75 | -1050 | -1575 | -73.8 | -64574.94 | -80324.92 | -236250.35 | -9.75 |
| Surprise | -42 | -9.71 | -5.88 | -3755.5 | 1155 | -2485 | -1884.75 | 40.8 | 44624.96 | 44099.96 | 110775.48 | 6.3203 |
| Surprise Percentage | -23.622% | -3.891% | -54.3438% | -580% | 55.6962% | -236.6667% | -119.6667% | 55.2846% | 69.1057% | 54.902% | 46.889% | 64.8236% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: JAGX
2026-07-29 00:40:19
Jaguar Health, Inc. announced positive findings from exploratory surveys of dog owners and veterinary oncologists regarding their new product, Neonorm Dog. This plant-based, non-prescription product is designed to support normal stool consistency and GI fluid balance in dogs, extending Jaguar's existing Neonorm franchise. The company plans to make Neonorm Dog available through Amazon and Chewy, aiming to broaden its commercial footprint in the companion animal market.
2026-07-28 19:10:47
Jaguar Health, Inc. (MUN:1JA1) reported a total revenue of €9.80 million last year, with its Human Health segment contributing the majority at €9.50 million. The United States was the primary revenue source, accounting for €9.80 million. This marks a decrease from the previous year's total revenue of €10.99 million and a U.S. contribution of €11.29 million.
2026-07-28 13:10:47
Jaguar Health (NASDAQ: JAGX) announced positive exploratory market research findings for its new product, Neonorm Dog, a plant-based, non-prescription product for canine GI health. Surveys indicated that nearly 80% of veterinary oncologists would recommend it for select canine oncology patients, and 94% of surveyed dog owners would likely purchase it. Jaguar Health plans to launch Neonorm Dog on platforms like Amazon and Chewy to expand its presence in the companion animal market.
2026-07-28 13:00:00
Jaguar Health announced positive findings from consumer and veterinary market research for its new product, Neonorm Dog. The plant-based product aims to support normal stool consistency and GI fluid balance in dogs. The company plans to launch Neonorm Dog through online channels like Amazon and Chewy, expanding its commercial footprint in the companion animal market.
2026-07-28 12:10:54
This article provides details on the institutional confidence score for Jaguar Health Inc (JAGX), along with its current stock price and key financial metrics. It highlights significant changes in institutional shareholdings, particularly by Mailman (Josh), Iliad Research & Trading, L.P., and UBS Financial Services, Inc., indicating varying levels of confidence in the company.
2026-07-28 09:00:00
Jaguar Health, Inc. announced positive market research supporting the commercial opportunity for its new product, Neonorm Dog. Surveys of dog owners and veterinary oncologists indicated significant interest and a perceived unmet need for a plant-based digestive support product for dogs, especially for those with loose stools. Jaguar plans to launch Neonorm Dog through online and retail channels, including Amazon and Chewy, expanding its reach in the companion animal market.
